Hercules Capital

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immunologic diseases. The company specializes in leveraging Nanobody technology to create new treatments aimed at addressing inflammatory conditions, particularly in the skin and joints. Its lead investigational product, Sonelokimab, represents a novel approach to managing inflammation, with the potential to significantly improve patient outcomes. Through its research and development efforts, MoonLake aims to advance the understanding and treatment of various inflammatory diseases, contributing to the evolving landscape of biopharmaceuticals.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Job&Talent is a leading marketplace for essential work, specializing in matching individuals with companies through its advanced platform. Founded in 2009 and headquartered in Madrid, the company utilizes technology to simplify the hiring process, offering services that include messaging, in-application hiring, staffing, and payroll management. This innovative approach leverages big-data matching technology to enhance recruitment efficiency and quality. In 2022, Job&Talent successfully placed over 340,000 workers in more than 2,500 companies, generating €1.9 billion in revenue. Operating in ten countries across Europe, the U.S., and Latin America, Job&Talent is recognized as the highest-valued unicorn in Spain, with a valuation of $2.4 billion and support from prominent investors. The company is committed to expanding its reach and continuing to deliver reliable, flexible work solutions for both job seekers and employers.

Remodel Health is a technology company that specializes in employee health benefits. It offers a user-friendly software platform that assists businesses in transitioning to Individual Coverage Health Reimbursement Arrangements (ICHRA), providing more tailored and cost-effective health benefits to their employees. The platform simplifies the process for employers and brokers, helping businesses of all sizes retain employees by offering personalized health benefits solutions.

Omio is a travel platform founded in 2012 and headquartered in Berlin, Germany. It enables users to compare, plan, and book various modes of transportation, including trains, buses, and flights. The platform features a multi-mode search tool that pulls data from diverse sources to suggest optimal travel routes and nearby airports, allowing users to visualize and compare options based on cost and travel time. Omio focuses on long-distance travel planning, providing real-time price comparisons and booking capabilities tailored to individual preferences for dates and locations. The service caters to travel enthusiasts seeking a simple, flexible, and personalized way to organize their journeys.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Behavox Ltd. is a London-based company that specializes in compliance surveillance software for the capital markets sector. Established in 2014, Behavox offers an enterprise platform that consolidates various types of employee-generated data into a unified data lake, enabling real-time querying and analysis. Its primary products include Behavox Compliance, which monitors employee activities and assesses risk, and Behavox Voice, a tool for processing and analyzing voice recordings with multi-lingual capabilities. The company's technology leverages machine learning and artificial intelligence to enhance detection algorithms for identifying misconduct, insider threats, and other forms of market abuse. By applying advanced academic research and sophisticated engineering, Behavox aims to provide innovative solutions that improve compliance, corporate culture, and operational competitiveness for large financial institutions. Additionally, the company maintains strategic partnerships to further enhance its offerings.

Smartsheet Inc. is a cloud-based platform designed for effective work execution, enabling organizations to manage projects, programs, and processes with enhanced efficiency. Founded in 2005 and headquartered in Bellevue, Washington, Smartsheet provides a range of collaborative tools tailored to various business needs. Its offerings include Smartdashboards for real-time visibility, Smartportals for easy access to project resources, Smartcards for workflow organization, and Smartgrids for tracking multiple tasks. The platform also features Smartprojects for team collaboration, Smartcalendars for aligning deadlines, Smartforms for structured information collection, and Smartautomation for process automation. Additionally, Smartsheet integrates with existing enterprise applications, facilitating seamless operations across diverse sectors such as aerospace, healthcare, finance, and technology. The company generates revenue through software subscriptions and additional charges for enhanced platform capabilities.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Thumbtack, Inc. is an online services marketplace based in San Francisco, California, that connects homeowners with skilled professionals across various fields. Established in 2008, the platform enables users to find and hire service providers such as movers, contractors, plumbers, electricians, and photographers, among others. Thumbtack offers personalized guidance to homeowners, helping them understand what tasks need to be completed and when, while providing access to a network of approximately 300,000 local service businesses. The platform not only facilitates hiring for home improvement and maintenance but also covers a broad range of services, including event management, health and wellness, personal counseling, and technical support. By analyzing bids from professionals, Thumbtack helps users determine the true cost of their projects, making the process of managing home services more straightforward and efficient.

Pindrop is a developer of advanced phone fraud detection and call center authentication technology, focused on enhancing security, identity, and trust in voice interactions. The company offers solutions that authenticate phone devices through call audio analysis, enabling the detection of fraudulent calls and the verification of legitimate callers. By leveraging a comprehensive risk database, Pindrop's technology helps enterprise call centers and businesses streamline communication, reduce call handling time, and improve customer experience while minimizing fraud losses. With a commitment to unlocking the value of voice interactions, Pindrop is positioned to support both enterprises and consumers in navigating a voice-driven future.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Semperis, Inc. is an enterprise identity protection company that specializes in safeguarding and recovering Active Directory environments from cyber breaches and identity system failures. Founded in 2013 and headquartered in New York, with an additional location in Ramat Gan, Israel, Semperis provides a suite of solutions, including the Directory Services Protector, which allows organizations to automatically restore an entire Active Directory forest and quickly recover critical attributes. Their offerings also include the Active Directory Forest Recovery and the Active Directory State Manager, which facilitate real-time granular searches, comparisons, and restorations of attributes. Semperis serves a diverse range of industries, including financial services, healthcare, and government, helping clients enhance their cyber resilience and protect against data breaches and operational errors.

Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.

Harness, Inc. is a technology company that develops a Continuous Delivery-as-a-Service platform aimed at simplifying the software delivery process for engineering and DevOps teams. Founded in 2015 and headquartered in San Francisco, California, the platform leverages machine learning to automate various aspects of code deployment, including test prioritization, cloud cost management, and continuous verification. Key features of Harness's platform include a pipeline builder, workflow wizard, automated rollback capabilities, secrets management, audit trails, and real-time delivery analytics. By streamlining these processes, Harness enables organizations to accelerate their cloud initiatives and enhance their adoption of modern containerization and orchestration technologies.

Electric Hydrogen is a company focused on developing low-cost, high-efficiency, fossil-free hydrogen systems aimed at decarbonizing industrial sectors such as ammonia and steel production, which are significant contributors to global greenhouse gas emissions. By rethinking electrolysis, Electric Hydrogen seeks to make clean hydrogen competitive with traditional, fossil-fuel-based hydrogen in terms of cost and scalability. The company's advanced PEM technology utilizes low-cost renewable electricity to produce clean hydrogen gas, thereby helping industries reduce their reliance on fossil fuels and minimize pollution. With a leadership team experienced in transformative clean energy companies, Electric Hydrogen is positioned to address current challenges in efficiency and cost, contributing to the goal of a zero-emission industrial sector in the near future.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Reveleer is a healthcare software and services company that operates a Software-as-a-Service analytics platform focused on medical record analysis and targeted solutions. Founded in 2009 and based in Glendale, California, the company enables payers across Medicare, Medicaid, and commercial sectors to effectively manage risk adjustment and quality improvement programs. Reveleer's platform provides a comprehensive suite of services, including medical record collection, retrieval, coding, and abstraction, all integrated into a single system. Additionally, the company offers professional services such as abstractor training, auditing, and strategic assessments to enhance operational practices and data management. Formerly known as Health Data Vision, Inc., Reveleer rebranded in August 2019 to reflect its commitment to empowering healthcare organizations to take control of their data and improve coding accuracy.

Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Shield AI Inc is an artificial intelligence robotics company based in San Diego, California, focused on developing advanced AI-powered systems for national security and first responders. Incorporated in 2015, the company specializes in creating technologies that enhance the safety of military personnel and civilians. Its flagship products include Nova, an autonomous quadcopter drone equipped with lidar technology that operates effectively in GPS-denied environments, and Hivemind, an AI framework that allows various unmanned vehicles to learn from real and synthetic experiences, enabling autonomous operations without direct human control. Additionally, Shield AI has developed the V-BAT, a vertical takeoff and landing aircraft that can navigate contested environments and has been utilized in regions like the Black Sea and the Middle East. The company aims to transform defense operations by leveraging cutting-edge AI and machine learning technologies to execute complex tasks in dynamic and denied environments.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company offers a comprehensive digital platform that combines artificial intelligence with human support, providing users access to coaches, nutritionists, diabetes educators, nurses, trainers, and licensed therapists. This platform features personalized content, lessons, and habit recommendations, along with video sessions and messaging to facilitate communication. Vida Health's approach aims to treat the whole health of individuals by integrating mental and physical care, helping users prevent, manage, and potentially reverse chronic conditions such as diabetes and hypertension, as well as associated mental health issues like stress, depression, and anxiety. Founded in 2014, Vida Health has earned the trust of major employers and health plans in the United States for its clinically validated services.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Eat Just, Inc., founded in 2011 and based in San Francisco, California, focuses on creating plant-based food products aimed at improving the food system. The company offers a variety of items, including plant-based scrambled eggs, flavored mayonnaise, dressings, cookie doughs, and meat alternatives. Their flagship product, JUST Egg, has garnered significant recognition, being featured in lists such as Popular Science's "100 Greatest Innovations." Eat Just emphasizes innovation through a unique discovery platform for food ingredients, combining scientific research with culinary expertise from Michelin-starred chefs. The company has been acknowledged in various prestigious lists, including Fast Company’s "Most Innovative Companies" and Entrepreneur’s "100 Brilliant Companies."

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Heron Therapeutics is a biotechnology company dedicated to developing innovative treatments for unmet medical needs, primarily in the area of nausea and pain management. Utilizing its proprietary Biochronomer drug delivery technology, the company provides sustained therapeutic levels of short-acting pharmacological agents with a single administration over several days. Heron's product offerings include SUSTOL, an extended-release injection designed to prevent nausea and vomiting associated with certain chemotherapy regimens, and CINVANTI, an intravenous formulation for managing nausea linked to highly emetogenic chemotherapy. The company is also advancing investigational products such as HTX-011, a dual-acting combination of bupivacaine and meloxicam currently in Phase III trials for pain management, and HTX-034 for postoperative pain. Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Tipalti, Inc., established in 2010, specializes in accounts payable automation and global mass payments. Headquartered in San Mateo, California, with an additional office in Israel, the company offers a comprehensive software solution that streamlines and automates the process of paying suppliers, partners, and publishers worldwide. Tipalti's platform covers all aspects of the payables workflow, including supplier onboarding, invoice processing, global funds disbursement, tax compliance, and payment reconciliation. By utilizing Tipalti, businesses can significantly reduce their supplier payment workload, strengthen financial controls, ensure regulatory compliance, and improve partner payment experiences, enabling them to focus on strategic growth.

Skydio, Inc. is a drone manufacturer based in Redwood City, California, founded in 2014. The company designs, assembles, and supports advanced drones that leverage artificial intelligence to enhance user experience. Skydio's drones are utilized in various sectors, including public safety, inspection, and defense, catering to consumers, enterprises, and government customers. Their products feature an array of cameras and proprietary computer vision technology that allows for real-time obstacle recognition and avoidance, enabling autonomous flight and intelligent decision-making. The company's initial offering was the R1 drone, which could autonomously track and film targets without human intervention. This was followed by the Skydio 2, which was more affordable and boasted improved tracking capabilities. The flagship model, the X2, is equipped with advanced features such as night vision and 100x zoom, allowing ordinary users to operate drones with ease. Skydio is supported by prominent investors and strategic partners, contributing to its growth in the competitive drone market.

AmplifyBio is a biotechnology company established in 2021 and headquartered in West Jefferson, Ohio. The company specializes in developing next-generation cell and gene therapies, with a focus on advancing human health through innovative treatment solutions. AmplifyBio's platform emphasizes research and development in areas such as vaccine technologies, bioanalytics, and drug development, aiming to accelerate the creation of therapies and vaccines. By leveraging cutting-edge technologies and novel research methodologies, AmplifyBio seeks to contribute to medical breakthroughs and improve access to effective treatments for a wide range of diseases.

Locus Robotics Corp. develops and manufactures autonomous mobile robots designed to enhance fulfillment operations in warehouses and e-commerce settings. Founded in 2014 and headquartered in Wilmington, Massachusetts, the company offers LocusBots, which can work with various containers and incorporate special peripherals to streamline order processing. These robots are engineered to collaborate with human workers, significantly increasing order productivity and fulfillment speed, achieving 2 to 3 times the throughput with near-perfect order accuracy. Locus Robotics serves a range of clients, including retailers, manufacturers, and third-party logistics providers, helping them efficiently manage high order volumes and meet the growing demands of e-commerce and omnichannel fulfillment.

Oak Street Health, Inc. is a healthcare provider that operates a network of primary care centers specifically designed to serve Medicare beneficiaries in medically underserved communities across the United States. Founded in 2012 and headquartered in Chicago, Illinois, the company prioritizes a value-based care model over a volume-based approach, emphasizing comprehensive preventive care. Oak Street Health offers personalized wellness plans, integrated health services, and educational and social activities aimed at improving health outcomes for older adults while also lowering medical costs. As of September 2020, it operated 67 centers in various states, including Illinois, Indiana, and Texas, addressing the significant gap in quality healthcare available to its target population.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Bright Machines, Inc. is a manufacturing company founded in 2018 and based in San Francisco, California, with additional offices in Tel Aviv, China, and Mexico. The company specializes in creating robotic arms and cells for micro factories, focusing on the assembly and inspection of electronic products. It aims to reduce manual labor in manufacturing by integrating advanced robotics with a software-defined manufacturing platform. This platform leverages artificial intelligence, machine learning, and production data to enhance automation processes, resulting in robots that are adaptable and equipped with sensor technology and computer vision. Bright Machines enables its clients to innovate rapidly and achieve better production yields at lower costs, meeting the evolving demands of the manufacturing sector.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in the development of AI-powered software solutions designed to enhance business efficiency. Founded in 2003 and headquartered in San Jose, California, the company offers a cloud-native platform that integrates RPA with artificial intelligence, machine learning, and analytics. Its flagship products include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server for streamlined business operations; and IQ Bot, a cognitive automation solution that addresses complex business tasks. Additionally, the company provides a comprehensive suite of testing tools, such as Testing Anywhere, which supports quality assurance across various platforms. Automation Anywhere also offers consulting services and collaborates strategically with Microsoft Azure. The company has expanded its presence internationally with offices in several major cities across the United States, Europe, the Middle East, and Asia.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in West Conshohocken, Pennsylvania, that specializes in developing therapeutics for cardiovascular, metabolic, and liver diseases. The company’s lead product, MGL-3196, is an orally administered small-molecule, liver-directed thyroid hormone receptor (THR) ß-selective agonist, currently in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Additionally, Madrigal is advancing MGL-3745, another THR-ß-selective small molecule, which is in preclinical trials aimed at addressing NASH and hyperlipidemia. The company has established a research and development agreement with Hoffmann-La Roche to support its efforts in utilizing and commercializing various licensed products. Through its innovative approach, Madrigal Pharmaceuticals aims to address both niche and prevalent conditions, including diabetes and dyslipidemia.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods, ranging from single pallets to full truckloads. The company offers a mobile application that features real-time shipment tracking, status updates, and ensures on-time deliveries. Founded in 2015 and based in Seattle, Washington, Convoy aims to enhance efficiency in the trucking industry, which is valued at $800 billion and is responsible for significant carbon emissions from empty trucks. By utilizing technology and data, Convoy addresses issues of waste and inefficiency, ultimately saving money for shippers, increasing earnings for drivers, and reducing carbon waste. The platform facilitates instant quotations, online bookings, automated loading suggestions, and online payments, all of which contribute to improved operational efficiency and cost reduction for clients.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Carwow Ltd. operates an online platform that simplifies the process of buying new cars by connecting consumers with dealerships. The platform allows users to compare offers on configured cars, facilitating a more transparent and efficient purchasing experience without the need for haggling. Carwow also provides valuable buying advice, including car reviews, recommendations for choosing the right vehicle, and guidance on financing and selling cars. Founded in 2009 and based in London, the company aims to enhance the car buying experience by streamlining interactions between buyers and official dealers, ultimately improving stock turnover for dealerships while helping consumers find reasonable prices. Carwow was previously known as Digital Blurb Limited before rebranding in May 2013.

Esme Learning Solutions LLC, based in Charlestown, Massachusetts, specializes in online learning solutions for executives and working professionals. It delivers transformational learning experiences through video conference calls and online programs, supporting individual learners, universities, and corporations. The company's AI-based platform offers personalized courses in emerging fields like blockchain and fintech, enabling users to design engaging online teaching programs for time-pressed executives.

Lucira Health, Inc. is a medical technology company based in Emeryville, California, that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013, the company focuses on creating accessible and user-friendly testing solutions, including a disposable COVID-19 test kit designed for home use. This kit provides centralized-laboratory-accurate molecular testing in a compact format that operates on two AA batteries. It connects consumers to treatment options through a mobile application and offers a dual testing capability to determine whether viral respiratory symptoms are caused by COVID-19 or influenza. Lucira Health aims to enhance the accessibility and efficiency of infectious disease diagnostics.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Carwow Ltd. operates an online platform that simplifies the process of buying new cars by connecting consumers with dealerships. The platform allows users to compare offers on configured cars, facilitating a more transparent and efficient purchasing experience without the need for haggling. Carwow also provides valuable buying advice, including car reviews, recommendations for choosing the right vehicle, and guidance on financing and selling cars. Founded in 2009 and based in London, the company aims to enhance the car buying experience by streamlining interactions between buyers and official dealers, ultimately improving stock turnover for dealerships while helping consumers find reasonable prices. Carwow was previously known as Digital Blurb Limited before rebranding in May 2013.

FTX is a cryptocurrency exchange company that specializes in developing a professional trading platform, supporting features such as quarterly and perpetual futures, leveraged tokens, and OTC trading. It aims to cater to both professional trading firms and first-time users, offering an intuitive and robust trading environment. FTX was incubated by Alameda Research, ensuring it had industry order books from its inception. Additionally, FTX Ventures, its investment arm, provides equity and/or token investments to blockchain companies at various stages, supporting founders and maintaining their decision-making flexibility.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers several products, including the Clonidine Transdermal Delivery System for hypertension and Fentanyl Transdermal Delivery System for chronic pain management. Corium's pipeline includes the Twirla contraceptive patch, MicroCor hPTH(1-34) for osteoporosis, and transdermal systems for Alzheimer's disease treatment. Additionally, the company is developing Aripiprazole and Corplex Ropinirole patches targeting psychiatric disorders and Parkinson's disease, respectively. Corium has established collaborations with several pharmaceutical companies and aims to enhance therapeutic options in central nervous system healthcare. The firm has been operational since 1995 and continues to advance its innovative drug delivery technologies.

3Gtms, Inc. is a provider of multi-modal transportation management software solutions designed for shippers, logistics service providers, carriers, third-party logistics providers, freight brokers, and freight auditors. Founded in 2010 and headquartered in Shelton, Connecticut, with additional offices in Raleigh, North Carolina, Utrecht in the Netherlands, and Wayne, Pennsylvania, the company offers a comprehensive Transportation Management Suite that encompasses the entire transportation lifecycle, including rating, routing, tendering, tracking, and settlement. 3Gtms also features specialized solutions such as the Contract Management Suite and the LTL Rate Management Suite, which provide innovative alternatives to traditional rating tools. The company's cloud-based and on-premise offerings are complemented by support, training, and consulting services. 3Gtms has established a strategic alliance with Trimble, further enhancing its capabilities in transportation management.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Better Therapeutics is a company focused on the discovery, development, and commercialization of prescription digital therapeutics aimed at treating cardiovascular and metabolic diseases. It utilizes clinically validated, FDA-regulated software to promote behavior changes that address the underlying causes of these conditions, thereby enhancing quality of life, reducing reliance on medications, and lowering healthcare costs. The company's offerings include digital behavioral therapy that combines neuroscience, lifestyle medicine, and explainable artificial intelligence through a physician-prescribed mobile medical app. This approach leverages patient-generated data to guide clinical decision-making and optimize treatment outcomes. Better Therapeutics' current product pipeline features therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

Novelion Therapeutics Inc. is a biopharmaceutical company based in Vancouver, Canada, focused on developing therapies for individuals with rare diseases. The company offers commercial products, including metreleptin, which treats complications of leptin deficiency in patients with generalized lipodystrophy, marketed under the MYALEPTA brand, and lomitapide capsules for adult patients with homozygous familial hypercholesterolemia, sold as JUXTAPID and LOJUXTA. Novelion also invests in the development of innovative therapies, including zuretinol acetate for treating inherited retinal diseases linked to mutations in specific genes. Originally founded in 1981 as QLT Inc., the company rebranded to Novelion Therapeutics in 2016 and operates through its subsidiary, Aegerion Pharmaceuticals, which is dedicated to addressing the needs of patients with debilitating rare diseases.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is an innovative oral and intravenous treatment aimed at addressing various fungal infections, including vulvovaginal candidiasis and invasive candidiasis. The drug has successfully completed Phase 2 clinical trials for vulvovaginal candidiasis. Additionally, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials, antivirals, and oncology. The company also provides contract research services, such as medicinal chemistry and cGMP manufacturing, to pharmaceutical and life science partners. Founded in 1999 and originally known as SCYNEXIS Chemistry & Automation, Inc., the company changed its name in 2002 and is headquartered in Jersey City, New Jersey.

Plaid Inc. is a technology company that facilitates the connection between consumers' bank accounts and applications, aiming to democratize financial services through advanced technological solutions. Founded in 2012 and headquartered in San Francisco, it provides a comprehensive suite of APIs that enable developers to create financial products connecting users with traditional financial institutions. Plaid's offerings include tools for accessing transaction history and balance data, authenticating bank accounts for payments, verifying identities, and confirming real-time account balances and income. These products support various applications in personal finances, consumer payments, lending, banking, and business finance. With a focus on enhancing both consumer experiences and developer capabilities, Plaid serves a diverse range of clients, including Fortune 50 companies, positioning itself as a vital infrastructure provider in the digital financial landscape.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Raydium is an automated market maker (AMM) operating on the Solana blockchain, designed to enhance trading efficiency through its integration with the Serum decentralized exchange's central order book. By providing on-chain liquidity to Serum's central limit order book, Raydium allows users and liquidity pools to access the full order flow and liquidity of the Serum ecosystem. This innovative platform facilitates rapid trades and shared liquidity, while also offering features for earning yield. Raydium's architecture supports a fast and effective trading environment, catering to the needs of both traders and liquidity providers.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

CloudBolt Software, Inc. is a provider of a cloud management platform designed to help enterprises effectively manage and govern their hybrid cloud environments. Founded in 2012 and headquartered in Rockville, Maryland, with additional offices in various locations, CloudBolt offers a solution that integrates on-premises resources and public clouds into a single, user-friendly interface. Its platform enables organizations to quickly and securely configure and manage both private and public cloud resources while supporting DevOps and end-users with self-service provisioning capabilities. CloudBolt's offerings include OneFuse, a codeless integration platform for automating hybrid cloud technologies, and Kumolus, which focuses on optimizing and governing public cloud usage. The company serves a diverse range of industries, including financial services, healthcare, and technology, by providing tools for cost management and enhancing automation strategies.

Udacity, established in 2011, is a Mountain View, California-based online learning platform that specializes in providing industry-relevant skills training. It offers a range of nanodegree programs in areas such as artificial intelligence, machine learning, data science, and cloud computing, among others. Udacity's courses are designed to equip learners with the skills that employers value, and its credentials are endorsed by industry partners. The company aims to make education accessible and affordable, with a mission to help students worldwide secure the jobs they desire. Udacity has raised over $163 million from investors, including Andreessen Horowitz and GV, and is valued at over $1 billion.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats and digital communication risks. Its cloud-based platform offers real-time threat analytics, intelligence, and comprehensive protection to identify, manage, and mitigate potential cyber threats. ZeroFox's solutions include monitoring for phishing attacks, account compromises, impersonation, and various forms of fraud, ensuring proactive defense through integration with existing security measures. The company also provides specialized services such as employee protection for high-value individuals and election protection for political campaigns and organizations. Established in 2013 and headquartered in Baltimore, Maryland, with additional offices in London, Las Condes, and Bengaluru, ZeroFox serves a diverse range of industries, including financial services, healthcare, technology, and media. By leveraging advanced technology and a global perspective on social media threats, ZeroFox aims to safeguard organizations against the evolving landscape of digital risks.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.

Dashlane Inc., established in 2009, specializes in password management and digital security solutions. Headquartered in New York with offices in Paris and Lisbon, the company offers a software application that securely stores, manages, and autofills passwords, enabling users to log in and checkout swiftly across devices. Dashlane's solutions include a secure password vault, autofill for web forms, a digital wallet for receipt capture, and security features like strong password generation and inbox security scans. Its business-focused offerings, such as Dashlane Business 2.0, aim to enhance password security and reduce unsecure password sharing within organizations. With over 22,000 businesses and 19 million users globally, Dashlane simplifies and secures the digital experience for both individuals and enterprises.

Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative medicines aimed at improving the lives of patients suffering from immune-mediated diseases. The company's lead investigational drug, reproxalap, is a first-in-class treatment that is in late-stage development for dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing other product candidates for a range of conditions, including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, autoimmune diseases, and certain cancers. The company's efforts are dedicated to addressing unmet medical needs through the development of next-generation therapies.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

FuelCell Energy, Inc. is a company that specializes in the design, manufacture, sale, installation, operation, and servicing of stationary fuel cell power plants for distributed power generation. The company offers a range of products, including its SureSource line, which utilizes carbonate fuel cell technology for various applications such as on-site power generation, utility grid support, distributed hydrogen production, and micro-grid systems. Additionally, FuelCell Energy provides solutions for carbon capture and energy storage using solid oxide technology. Its products serve diverse markets, including utilities, industrial applications, education, healthcare, data centers, wastewater treatment, and commercial sectors. Founded in 1969 and headquartered in Danbury, Connecticut, FuelCell Energy primarily operates in the United States, South Korea, England, and Germany, focusing on decarbonizing energy strategies to support net-zero commitments.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for urologic conditions in the United States. The company's primary product candidate, vibegron, is an oral small molecule beta-3 agonist aimed at treating overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain associated with irritable bowel syndrome. Additionally, Urovant is investigating URO-902, a gene therapy designed for patients with OAB who have not responded to oral pharmacological treatments. Founded in 2016 and based in London, Urovant Sciences operates as a subsidiary of Sumitovant Biopharma Ltd.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Mesoblast Limited is a biopharmaceutical company specializing in the development and commercialization of allogeneic cellular medicines for a variety of complex diseases. Utilizing its proprietary Mesenchymal Precursor Cell (MPC) technology, the company addresses conditions resistant to conventional treatments, particularly those involving inflammation. Mesoblast's product pipeline includes MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain due to degenerative disc disease, among others. The company is also advancing MPC-300-IV, which targets biologic refractory rheumatoid arthritis and diabetic kidney diseases in Phase II clinical trials. Headquartered in Melbourne, Australia, Mesoblast operates in multiple countries, including the United States, and has formed strategic partnerships with various pharmaceutical companies to enhance its product offerings and expand its market reach. Founded in 2004, Mesoblast aims to provide innovative therapies in fields such as oncology, hematology, and orthopedic disorders.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Contentful GmbH, established in 2011, is a technology company headquartered in Berlin, Germany, with additional offices in San Francisco and Denver. It specializes in developing a cloud-based content management platform, Contentful, designed to streamline digital experiences for businesses. Contentful enables companies to create, manage, and distribute content across multiple channels, including web and mobile applications, at a faster pace and larger scale than traditional CMS solutions. It unifies content in a single hub, structures it for use in any digital channel, and integrates seamlessly with other tools through open APIs. Contentful serves a diverse range of clients, including 30% of the Fortune 500 and prominent brands like Chanel, Shopify, and BP.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.

Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

CloudPay is a provider of managed global payroll services, offering a unified cloud-based platform designed for multinational organizations. Its solution delivers end-to-end payroll management, ensuring consistent and compliant payroll processing across over 130 countries in more than twenty-five languages. By standardizing payroll functions, CloudPay helps organizations enhance efficiency, streamline compliance, and gain better visibility into payroll performance and costs. The company leverages over twenty years of industry experience and has successfully served more than 2,500 multinational entities. CloudPay has been recognized for its innovative technology and service, receiving multiple awards, including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

RumbleON is a United States-based online retailer specializing in the buying, selling, trading, and financing of pre-owned motorcycles, with a particular focus on Harley-Davidson. The company aims to provide consumers and dealers with an efficient, fast, and transparent experience. Its primary revenue comes from the powersports segment, which includes motorcycles and other recreational vehicles, while the automotive segment expands its offerings to cars and trucks. Additionally, RumbleON provides nationwide vehicle logistics and transportation services, facilitating the movement of vehicles between dealerships. Through its comprehensive platform, RumbleON enhances the accessibility and convenience of engaging in the pre-owned vehicle market.

Dashlane Inc., established in 2009, specializes in password management and digital security solutions. Headquartered in New York with offices in Paris and Lisbon, the company offers a software application that securely stores, manages, and autofills passwords, enabling users to log in and checkout swiftly across devices. Dashlane's solutions include a secure password vault, autofill for web forms, a digital wallet for receipt capture, and security features like strong password generation and inbox security scans. Its business-focused offerings, such as Dashlane Business 2.0, aim to enhance password security and reduce unsecure password sharing within organizations. With over 22,000 businesses and 19 million users globally, Dashlane simplifies and secures the digital experience for both individuals and enterprises.

Metalysis Limited is a technology company based in Rotherham, United Kingdom, specializing in the manufacture of high-value metals and alloys, including titanium and tantalum. Founded in 2001, the company employs a solid-state process developed from research at the University of Cambridge to produce metal alloy powders that are primarily utilized in advanced manufacturing sectors such as aerospace and automotive. This innovative method is designed to be more environmentally friendly and energy-efficient compared to traditional melting technologies. Metalysis also provides powder metallurgy, additives, and analytical services, and has established commercial partnerships with various industry and academic entities. The company's Generation 4 technological expansion aims to scale production to industrial levels, further enhancing its capabilities in delivering 3D printable metal powders for diverse applications.

Gibraltar Business Capital, LLC, based in Northbrook, Illinois, provides working capital solutions to small and medium-sized businesses across various industries. Established in 1951, the firm specializes in asset-based loans and factoring, offering services such as invoice factoring, revolving lines of credit, and equipment term loans. Gibraltar Business Capital caters to companies facing financial challenges, including those with limited operating history, negative cash flow, or fluctuating sales. The company collaborates closely with business owners, advisors, and financial sponsors to deliver tailored capital solutions that address specific needs, facilitating growth and stability. Its flexible and accessible funding alternatives serve as a critical resource in today's dynamic marketplace, ensuring businesses can navigate financial hurdles effectively.